* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Problem set answers
Magnesium transporter wikipedia , lookup
Silencer (genetics) wikipedia , lookup
Gene expression wikipedia , lookup
Polyclonal B cell response wikipedia , lookup
Biochemistry wikipedia , lookup
Lipid signaling wikipedia , lookup
Catalytic triad wikipedia , lookup
Oxidative phosphorylation wikipedia , lookup
Drug design wikipedia , lookup
Amino acid synthesis wikipedia , lookup
Ultrasensitivity wikipedia , lookup
NADH:ubiquinone oxidoreductase (H+-translocating) wikipedia , lookup
Evolution of metal ions in biological systems wikipedia , lookup
Protein–protein interaction wikipedia , lookup
Epitranscriptome wikipedia , lookup
Protein purification wikipedia , lookup
Biochemical cascade wikipedia , lookup
Proteolysis wikipedia , lookup
Enzyme inhibitor wikipedia , lookup
G protein–coupled receptor wikipedia , lookup
Point mutation wikipedia , lookup
Biosynthesis wikipedia , lookup
Clinical neurochemistry wikipedia , lookup
Metalloprotein wikipedia , lookup
Paracrine signalling wikipedia , lookup
Signal transduction wikipedia , lookup
Two-hybrid screening wikipedia , lookup
Western blot wikipedia , lookup
1. The crystal structure for the enzyme you are studying has recently been published. The structure reveals a Glu45 reside in the active site and you propose it represents a substrate binding residue. Sequence comparison among 5 orthologs of the enzyme shows Glu45 is absolutely conserved. Kinetic studies of an E45A point mutants results in a 103-fold lower Km for substrate and a 104-fold lower Vmax relative to wild type enzyme. Interpret these results with respect to the likely role of Glu45 in the catalytic cycle of the enzyme. The lower Vmax is consistent with the mutation resulting in a decreased kcat, which is what one would expect if Glu45 is a catalytic group in the active site. Therefore, the observed effect on Vmax is consistent with the hypothesis. The effect of the mutation on Km suggest one of two possibilities: This mutation could result in an increased binding affinity as evidenced by the decrease in Km. More likely, the enzyme follows steady state kinetics for which Km=k2/k1, for which a decrease in k2 (I.e., kcat) would result in a lower Km as observed. The data presented do not allow one to distinguish between the two alternative interpretations. 2. For the enzyme in question 1 you next prepare a E45D point mutant and repeat the kinetic studies. These studies show a Km that is statistically indistinguishable from wild type enzyme but a Vmax that is 10-fold lower. Interpret these new results with respect to the effect of the E45D point mutant. The 10-fold lower Vmax suggests that mutation of Glu45 to Asp is not a conservative mutation. Since the side chain of Asp is one methylene shorter than Glu, the results suggests a decrease in Vmax due to a correspondingly greater distance between the carboxlate side chain and intermediate in the reaction cycle with which it must interact. 3. Contrast the effect on pKa for an aspartate versus a lysine residue within a hydrophobic microenvironment of an enzyme active site. A hydrophobic microenvironment will result in a localized lower dielectric constant, which favors uncharged species. Therefore, the carboxylate side chain of aspartate will appear to have a higher pKa (favoring the uncharged protonated form over a broader pH range) and the lysine will exhibit a lowered pKa (favoring an uncharged unprotonated form over a broader pH range). 4. AlphaCP1 is a polyC/U binding protein that binds to polyC/U-containing 3' UTR regions of certain mRNA species to stabilize the message and suppress translation. Phosphorylation of aCP1 by S6 protein kinase is thought to result in reduced binding to the mRNA and release of the protein from the polyC/U region, allowing translation initiation. You have identified Ser395 as a putative phosphorylation site for S6 protein kinase. To test this hypothesis, you generate an aCP1S395A point mutant and find that it binds polyC/U but fails to undergo S6 protein kinasemediated phosphorylation. You are feeling pretty good about the data until your advisor voices a concern that the result is not conclusive since the mutation may have partially altered the structure of aCP1 in a way that allows mRNA binding but prevents binding of S6 kinase. Propose an experiment in sufficient detail that resolves this question. The question is whether S6 kinase can distinguish wild type from mutant αCP1. One way would be to express recombinant wild type and mutant αCP1. (If done in parallel this would also obviate potential differences due to differences in the preparation methods.) One would then measure the initial rate of S6 kinase-catalyzed phosphorylation of wild type αCP1 in order to determine Vmax and Km. One would then repeat the experiment at different constant concentrations of point mutant (which cannot be phosphorylated) and observe whether the mutant is a competitive inhibitor. A secondary plot of Km,apparent versus [mutant]o would allow determination of the KI, which should equal the Km for wild type protein if the kinase is unable to distinguish between the two proteins. 1/vo Increasing concentrations of mutant -Mutant 1/Km 1/Km,app Km,app 1/[aCP1]o Km [Mutant]o 6. Defend the statement that general acid catalysis in an enzyme catalyzed reaction is a type of proximity effect. Proximity effects in enzyme catalysis arise by the precise orientation of amino acid side chains within the active site. In the case of general acid catalysis, this precise orientation results in the weak acid group being positioned to optimally donate the proton within the catalytic cycle. Therefore, general acid catalysis during an enzyme reaction is a special case of a proximity effect. 7. In 25 words or less thoroughly but succinctly define entropy-enthalpy compensation. The unfavorable transition state entropy of activation (DS‡) is compensated by the favorable enthalpy of binding (DH) of the reactants in the active site. 8. A student in your lab is using a 125I-labeled peptide hormone to study its binding to a membrane receptor. When the radiolabeled hormone was purchased the product sheet listed a specific radioactivity of 53 milliCuries/mmole. If the half life for 125I is 60 days, what is the specific radioactivity of the probe after 45 days? Show your work. k = 0.693/60 days = 0.0116 days-1 Specific activity after 45 days = 53 mCi/mmole•e-0.0116 days-1•45 days = 53 mCi/mmole•0.59 = 32 mCi/mole 9. You are studying the role of mRNA binding proteins in translational regulation of gene expression. You have found in a genetic screen that the ubiquitin conjugating enzyme E2epf interacts with the RNA binding protein AUF1. To prove this interaction, you express E2epf as an N-terminal GST fusion protein and demonstrate in a glutathione-Sepharose pull down assay that 100 nM concentration of the fusion is able to bind AUF1 (see Lane 2 of attached figure). As a control, 100 nM GST alone fails to bind AUF1 (see Lane 1 of attached figure). 1 2 3 4 [In this variation on an IP assay, the glutathione binding domain Glutathione S-Transferase (GST) is genetically fused to the amino terminus of E2epf. The resulting chimeric protein is incubated with a putative ligand, after which glutathione-linked beads are added to precipitate your GST fusion protein and any bound ligand. The presence of bound ligand can be tested by Western blot, as displayed in the figure which has been stained with anti-AUF1 antibody.] The literature reports that AUF1 can bind another RNA binding protein aCP1; to confirm this, you incubate the same concentration of AUF1 with 100 nM GST-aCP1 (Lane 3 of figure). Out of curiosity, the last experiment is repeated but you also add 100 nM E2epf to the mixture of GST-aCP1 and AUF1 (Lane 4 of figure). Provide a succinct thermodynamic argument supporting the hypothesis that E2epf binds aCP1. For extra credit, is there an alternative hypothesis also consistent with the observations? Because the density of the AUF1 band is greater in lane 4, the Western blot suggests that a combination of aCP1 and E2epf bind AUF1 with greater affinity than either alone. Because E2epf and aCP1 each bind AUF1, one can construct the following model for the process: AUF1 + E2epf + aCP1 K-1 K-2 K-2 aCP1•AUF1 + E2epf AUF1•E2epf + aCP1 K-1 aCP1•AUF1•E2epf In the scheme, the equilibrium constants represent Kdissociation constants. Because the bands of bound AUF1 in lanes 2 and 3 are nearly equal, K-1 K-2 ; however, because the combination of E2epf and aCP1 bind AUF1 with greater affinity, K-1 K-1, requiring K-2 K-2. The model requires E2epf and aCP1 to form a complex which binds AUF1 tighter than either alone. The tighter binding can be most easily envisioned as involving additive binding surfaces, as shown schematically: E2epf AUF1 aCP1 There is one other model that is fits the available data that does not require additive binding: AUF1 can bind E2epf and aCP1 at different sites that result in a conformation change that makes the other component bind tighter. This model would follow the same scheme as above but not require interaction of E2epf and aCP1: E2epf AUF1 aCP1 10. The plasma membrane of human cells contains a ubiquitously distributed family of tissue-specific receptor complexes involved in regulating cell adhesion, growth, and differentiation. These complexes contain a member of the tetraspanin superfamily of transmembrane proteins that is non-covalently associated with one or more membrane receptors or glycoproteins. The tetraspanins also bind an additional 14 kDa subunit termed Leu-13. The complex present on B lymphocytes (a type of immune cell circulating in the blood) is reported to be composed of the tetraspanin CD81 (25 kDa) which is associated with the transmembrane receptor CD19 (91 kDa) and the 110 kDa transmembrane glycoprotein CD21 (see illustration). You have recently found that a protein kinase, PI 3-kinase, binds to the cytoplasmic side of CD19. CD21 Leu-13 outside Cell membrane cytoplasm CD81 PI 3-kinase CD19 In normal freshly isolated B lymphocytes and in cultured Daudi cells (an established leukemic B lymphocyte cell line used in tissue culturing) Leu-13 is absent from this complex or present at low levels. However, addition of pure recombinant Leu-13 to either fresh B lymphocytes or Daudi cells reversibly reconstitutes the complex. Reconstitution of the complex is accompanied by complete inhibition of cell division. In this experiment, cell division is quantitated by measuring the incorporation of the radioactive nucleotide 3Hthymidine into DNA during the 2 hours following addition of recombinant Leu13 to the cultures. You compare this data to an experiment conducted under identical conditions but with freshly isolated normal human B lymphocytes. Data for both experiments are summarized in Table 1 for experiments conducted at 37 oC. What is the quantitative difference, if any, in the binding of Leu-13 to CD81 present on normal B lymphocytes versus Daudi cells?